| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.50(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
39,487 |
99,487 |
200,738 |
249,694 |
| Total Sell Value |
$2,038,634 |
$4,824,734 |
$8,307,365 |
$10,494,293 |
| Total People Sold |
7 |
8 |
9 |
12 |
| Total Sell Transactions |
10 |
12 |
21 |
35 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pinion John Richard |
See Remarks |
• – – |
2020-04-19 |
4 |
D |
$58.57 |
$14,525 |
D/D |
(248) |
49,239 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2020-03-12 |
4 |
OE |
$3.01 |
$449,998 |
D/D |
149,700 |
654,500 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-03-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
4,400 |
19,958 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$46,210 |
D/D |
(824) |
24,572 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,087 |
25,396 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$115,917 |
D/D |
(2,067) |
102,171 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,434 |
104,109 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$118,777 |
D/D |
(2,118) |
30,400 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,434 |
32,518 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$70,044 |
D/D |
(1,249) |
36,300 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,934 |
37,549 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$130,386 |
D/D |
(2,325) |
103,832 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,634 |
106,157 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$99,766 |
D/D |
(1,779) |
35,475 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,434 |
37,013 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-03-01 |
4 |
D |
$56.08 |
$21,759 |
D/D |
(388) |
17,058 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
17,446 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2020-03-01 |
4 |
A |
$56.08 |
$173,007 |
D/D |
3,085 |
49,487 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,434 |
52,572 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2020-03-01 |
4 |
D |
$56.08 |
$386,728 |
D/D |
(6,896) |
504,800 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
35,782 |
511,696 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2020-01-30 |
4 |
D |
$53.23 |
$86,446 |
D/D |
(1,624) |
24,615 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2020-01-14 |
4 |
AS |
$61.00 |
$61,000 |
D/D |
(1,000) |
15,946 |
|
15% |
|
| Kakkis Emil D |
President & CEO |
• • – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,435 |
475,914 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
23,579 |
|
- |
|
628 Records found
|
|
Page 12 of 26 |
|
|
1.49 (3.62%) 
